



Item 8.01 Other Events.

On June 13, 2012, Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has accepted for filing the Company's New Drug Application for its investigational drug candidate, Cysteamine Bitartrate Delayed-release Capsules ("RP103"), for the potential treatment of nephropathic cystinosis. The FDA has granted Standard Review designation for RP103. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit	Filed Here Incorporated by Reference with Form File No. Exhibit Filing Date Filed By
No. Exhibit Description	
99.1 Press release issued by the Company dated as of June 13, 2012	X

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RAPTOR PHARMACEUTICAL CORP.

Date: June 13, 2012 By: /s/ Kim R. Tsuchimoto  
Name: Kim R. Tsuchimoto  
Title: Chief Financial Officer, Treasurer and Secretary

---

Edgar Filing: Raptor Pharmaceutical Corp - Form 8-K

Exhibit Index

Exhibit No.	Exhibit Description	Filed Here Incorporated by Reference with FormFile No. Exhibit Filing Date Filed By
99.1	Press release issued by the Company dated as of June 13, 2012	X